Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

Sandra M. Swain, Gong Tang, Charles E. Geyer Jr, Priya Rastogi, James N. Atkins, Paul P. Donnellan, Louis Fehrenbacher, Catherine A. Azar, André Robidoux, Jonathan A. Polikoff, Adam M. Brufsky, David D. Biggs, Edward A. Levine, John L. Zapas, Louise Provencher, Donald W. Northfelt, Soonmyung Paik, Joseph P. Costantino, Eleftherios P. Mamounas, and Norman Wolmark

Author affiliations appear at the end of this article.

Published online ahead of print at www.jco.org on August 12, 2013.

Supported by Grants No. U10-CA-37377, U10-CA-12027, U10-CA-69651, and U10-CA-69974 (National Surgical Adjuvant Breast and Bowel Project) from the Public Health Service; No. CA 44066-25 (A.R./Centre hospitalier de l'Université de Montréal), and No. U10-CA-25224 (North Central Cancer Treatment Group) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Eli Lilly and Amgen provided funding and/or drug for this trial.

Presented at the 48th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2012.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical trial information: NCT00093795.

Corresponding author: Sandra M. Swain, MD, Washington Cancer Institute, MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC 20010; e-mail: sandra.m.swain@medstar.net.

© 2013 by American Society of Clinical Oncology

0732-183X/13/3126w-3197w/\$20.00

DOI: 10.1200/JCO.2012.48.1275

ABSTRACT

Purpose

Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. This trial (NSABP B-38; Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer) asked whether the incorporation of a fourth drug could improve outcomes relative to two standard regimens and provided a direct comparison of those two regimens.

Patients and Methods

We randomly assigned 4,894 women with node-positive early-stage breast cancer to six cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC), four cycles of dose-dense (DD) doxorubicin and cyclophosphamide followed by four cycles of DD paclitaxel (P; DD AC→P), or DD AC→P with four cycles of gemcitabine (G) added to the DD paclitaxel (DD AC→PG). Primary granulocyte colony-stimulating factor support was required; erythropoiesis-stimulating agents (ESAs) were used at the investigator's discretion.

Results

There were no significant differences in 5-year disease-free survival (DFS) between DD AC→PG and DD AC→P (80.6% v 82.2%; HR, 1.07; $P = .41$), between DD AC→PG and TAC (80.6% v 80.1%; HR, 0.93; $P = .39$), in 5-year overall survival (OS) between DD AC→PG and DD AC→P (90.8% v 89.1%; HR, 0.85; $P = .13$), between DD AC→PG and TAC (90.8% v 89.6%; HR, 0.86; $P = .17$), or between DD AC→P versus TAC for DFS (HR, 0.87; $P = .07$) and OS (HR, 1.01; $P = .96$). Grade 3 to 4 toxicities for TAC, DD AC→P, and DD AC→PG, respectively, were febrile neutropenia (9%, 3%, 3%; $P < .001$), sensory neuropathy (< 1%, 7%, 6%; $P < .001$), and diarrhea (7%, 2%, 2%; $P < .001$). Exploratory analyses for ESAs showed no association with DFS events (HR, 1.02; $P = .95$).

Conclusion

Adding G to DD AC→P did not improve outcomes. No significant differences in efficacy were identified between DD AC→P and TAC, although toxicity profiles differed.

J Clin Oncol 31:3197-3204. © 2013 by American Society of Clinical Oncology

INTRODUCTION

Adjuvant anthracycline- and taxane-based chemotherapy provides substantial benefits for women diagnosed with node-positive, early-stage breast cancer.¹⁻¹¹ However, a significant proportion of women treated with adjuvant chemotherapy still develop disease recurrence, which necessitates additional studies that evaluate alternative treatment strategies.

Doxorubicin (A) and cyclophosphamide (C) followed by paclitaxel (P) on a dose-dense (DD) schedule (DD AC→P) is considered an optimal

P-based adjuvant regimen for node-positive primary breast cancer.² The addition of gemcitabine (G) to P has shown improved outcomes in women with metastatic breast cancer. Therefore, in the National Surgical Adjuvant Breast and Bowel Project B-38 (NSABP B-38) trial (Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer), we chose to test whether the addition of a fourth agent, G, to DD AC→P (DD AC→PG) would provide a disease-free survival (DFS) benefit in the adjuvant setting.¹²⁻¹⁴ Moreover, because docetaxel, A, and C (TAC) is also considered an optimal

docetaxel-based adjuvant regimen, we designed this trial to also compare TAC with the investigational DD AC→PG regimen.^{3,9,10} Because TAC and DD AC→P have different toxicity profiles and have not been directly compared in a single prospective trial, this design provided an opportunity to directly compare toxicities and relative efficacy between these two standard regimens.

PATIENTS AND METHODS

Patients

Women with histologically proven node-positive invasive breast cancer who had undergone primary surgery with a total mastectomy or lumpectomy with clear margins of resection were eligible for random assignment. The following staging criteria were required: primary tumor stage pT1, pT2, or pT3 and ipsilateral lymph node stage pN1, pN2a, pN3a, or pN3b. Analysis of estrogen receptor (ER) expression and the intended plan for radiotherapy were required before entry into the study; progesterone receptor (PR) status was required if ER status was negative.¹⁵ Before random assignment, a history and physical examination, chest radiography, bilateral mammography, and electrocardiography were required. Patients with contralateral breast cancer or a prior history of breast cancer, including ductal carcinoma in situ, were excluded. Patients were also excluded if they had cardiac disease that precluded the use of anthracyclines, grade 2 or greater peripheral neuropathy, or if they were pregnant. Approximately 1 year after activation (in August 2005), the protocol was amended to exclude patients with human epidermal growth factor receptor type 2–positive tumors. Patients with human epidermal growth factor receptor type 2–positive tumors who initiated therapy before the amendment were allowed to receive trastuzumab following protocol therapy. The study was conducted after approval by the institutional review board or ethics committee of each participating institution. Written informed consent was required.

Study Design

The NSABP and members of the North American Breast Intergroup conducted this randomized phase III study. Patients were stratified according to the number of positive lymph nodes (1 to 3, 4 to 9, or ≥ 10), hormone receptor status (ER- and PR-negative, ER- and/or PR-positive), and type of surgery and planned radiotherapy (lumpectomy plus breast radiotherapy without regional nodal radiotherapy, lumpectomy plus breast radiotherapy with regional nodal radiotherapy, mastectomy without radiotherapy, and mastectomy with postmastectomy radiotherapy). After stratification, patients were randomly assigned by using a biased-coin minimization algorithm to one of the following three treatment regimens: (1) six cycles of concurrently administered A 50 mg/m² plus C 500 mg/m² plus docetaxel 75 mg/m² every 3 weeks (TAC), (2) four cycles of A 60 mg/m² plus C 600 mg/m² every 2 weeks followed by four cycles of P 175 mg/m² every 2 weeks (DD AC→P), or (3) four cycles of A 60 mg/m² plus C 600 mg/m² every 2 weeks followed by four cycles of P 175 mg/m² plus G 2,000 mg/m² every 2 weeks (DD AC→PG). Therapy was discontinued in the event of patient withdrawal, unacceptable toxicity, death, or at the discretion of the investigator.

All patients received primary prophylaxis with pegfilgrastim or filgrastim. Erythropoiesis-stimulating agents (ESAs) were allowed and recommended for hemoglobin ≤ 11 g/dL based on the approved package insert at the time. After completion of chemotherapy, patients with ER- and/or PR-positive tumors received endocrine therapy for a minimum of 5 years. Radiotherapy was to be administered after chemotherapy.

Clinical, hematologic, and biochemical assessments were required before each cycle and at 6-month intervals through year 5; clinical assessments were required every 12 months thereafter. Bilateral mammogram was required 12 months from the most recent examination before random assignment, and every 12 months thereafter. Assessments of toxic effects, according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3), occurred before each cycle starting with cycle 2; the final cycle was assessed at the end of that 21- or 14-day cycle, accordingly.

Statistical Analysis

The primary end point was DFS. Events included in DFS were local, regional, or distant breast cancer recurrence, second primary cancer (other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix), and death as a result of any cause if it occurred before these other events. Secondary end points were overall survival (OS), defined as death as a result of any cause; recurrence-free interval, defined as time to first local, regional, or distant recurrence; distant recurrence-free interval, defined as time to distant disease recurrence only; and toxicities of the drug regimens. The study was designed to detect a 25% reduction in the DFS event rate with DD AC→PG compared with both TAC and DD AC→P (90% power at a one-sided α level of .025), and the final analyses would be performed when the minimum number of DFS events in both pairs of the groups reached 613. The intention-to-treat principle was used for the primary analyses, which was performed on all randomly assigned patients with follow-up. The Kaplan-Meier method was used to estimate distributions of DFS and OS. Comparisons in DFS and OS among treatment arms were assessed by the stratified log-rank test, controlling for stratification factors. In addition, secondary treatment comparisons were performed in Cox models to control for additional prognostic variables (age, clinical tumor size). The Pearson χ^2 tests with continuity adjustment were used to compare toxicities among treatments and patient subgroups. All tests of significance were based on a two-sided P value using an α level of .05.

RESULTS

Patients

Between November 3, 2004, and May 3, 2007, 4,894 women were randomly assigned (TAC, 1,630; DD AC→P, 1,634; DD AC→PG, 1,630); of these, 4,859 had follow-up data and are included in this analysis (Fig 1). Clinical assessments on cancer recurrence or death were available for 4,841 patients (18 patients without an assessment of cancer status were alive at their last follow-up) and were the basis for the DFS comparison, as well as recurrence-free interval and distant

Fig 1. CONSORT diagram for enrollment, random assignment, and follow-up of study participants in National Surgical Adjuvant Breast and Bowel Project B-38 trial. AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; ER, estrogen receptor; PR, progesterone receptor; TAC, docetaxel, doxorubicin, and cyclophosphamide. (*) No follow-up available on 35 patients.

Table 1. Demographic and Baseline Characteristics of the NSABP B-38 Study Population

Characteristic	TAC (n = 1,630)		AC→P (n = 1,634)		AC→PG (n = 1,630)		P
	No.	%	No.	%	No.	%	
Age, years							.98
Median	51		51		51		
Range	25-79		24-81		22-82		
≤ 49	704	43	715	44	715	44	
50-59	588	36	600	37	595	37	
60-69	299	18	284	17	280	17	
≥ 70	39	2	35	2	40	2	
Menopausal status							.94
Premenopausal	741	45	756	46	752	46	
Postmenopausal	822	50	816	50	818	50	
Unknown	67	4	62	4	60	4	
No. of positive nodes							1.00
1-3	1,067	65	1,068	65	1,066	65	
4-9	405	25	409	25	404	25	
≥ 10	158	10	157	10	160	10	
Hormone receptor status*							1.00
Positive	1,296	80	1,299	80	1,296	80	
Negative	334	20	335	20	334	20	
Pathologic tumor size, cm							.64
0-2	656	40	630	39	668	41	
2.1-4	668	41	706	43	677	42	
> 4	239	15	236	14	225	14	
Unknown	67	4	62	4	60	4	
Type of surgery†							.97
Mastectomy	812	50	820	50	816	50	
Lumpectomy	751	46	762	47	754	47	
Unknown	67	4	62	4	60	4	
Type of radiation therapy							.32
Lumpectomy	751		762		754		
No radiotherapy reported	24	3	14	2	27	4	
Breast radiotherapy alone	341	45	339	44	328	44	
Breast plus regional radiotherapy	357	48	386	51	375	50	
Unknown	29	4	23	3	24	3	
Mastectomy	812		810		816		.52
No radiotherapy	290	36	282	34	279	34	
Local (chest wall) radiotherapy	158	19	139	17	160	20	
Regional radiotherapy	340	42	373	46	351	43	
Unknown	24	3	16	2	26	3	

Abbreviations: AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; NSABP B-38, National Surgical Adjuvant Breast and Bowel Project B-38 [trial]; TAC, docetaxel, doxorubicin and cyclophosphamide.

*Patients must have an estrogen receptor (ER) analysis performed on the primary tumor prior to random assignment. If ER analysis is negative, then progesterone receptor (PR) analysis must be performed. If ER analysis is positive, PR analysis is desired, but not mandatory. Marginal or borderline results (ie, those not definitely negative) were considered positive.

†Patients were required to have undergone primary breast cancer surgery to be eligible for study entry.

recurrence-free interval. The OS analysis was based on the 4,859 patients with follow-up.

Baseline characteristics were well balanced between the treatment groups (Table 1). Of the 2,267 patients having undergone lumpectomy, all but 65 (3%) received breast radiotherapy as mandated in the protocol. The majority of treated patients completed chemotherapy treatment as specified in the protocol (91% of patients in the TAC arm; 88% in the DD AC→P and DD AC→PG arms). Among the 4,883 patients with treatment information 4%, 9%, and 6% in these three arms, respectively, specifically discontinued protocol therapy because of adverse events or adverse effects (Appendix Table A1, online only). Of the 208 patients who received trastuzumab,

58 were in the TAC arm, 70 were in the DD AC→P arm, and 80 were in the DD AC→PG arm.

Efficacy

After a median follow-up of 64 months (range, 1 to 87 months), 941 DFS events had been reported (327 in the TAC arm, 294 in the DD AC→P arm, and 320 in the DD AC→PG arm). Distribution of the first DFS events by treatment arm is shown in Appendix Table A2 (online only). The 5-year DFS rate for DD AC→PG (the investigational arm) compared with DD AC→P was 80.6% versus 82.2% (hazard ratio [HR], 1.07; 95% CI, 0.91 to 1.26; $P = .41$). DFS for DD AC→PG compared with TAC was 80.6% versus 80.1% (HR, 0.93;

Fig 2. Disease-free survival and overall survival in National Surgical Adjuvant Breast and Bowel Project B-38 trial. Results of Kaplan-Meier analyses for (A) disease-free survival and for (B) overall survival across all three treatment arms. AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; HR, hazard ratio; TAC, docetaxel, doxorubicin, and cyclophosphamide.

95% CI, 0.80 to 1.09; $P = .39$). The HR for DFS of DD AC→P versus TAC was 0.87 (95% CI, 0.74 to 1.01; $P = .07$). Corresponding Kaplan-Meier curves are presented in Figure 2A. Forest plots providing the HR estimates together with their 95% CIs by stratification groups are shown in Figure 3; no significant treatment interactions were noted for any subgroup tested. DFS and comparisons among treatment arms by ER status and nodal status are shown in Appendix Figures A1 and A2 (online only). The results suggested that AC→P might be superior to TAC in DFS among patients with ER-negative tumors ($P = .09$) and those with one to three positive nodes ($P = .08$), although the differences were not statistically significant.

At the time of this analysis, 540 of the 4,859 patients had died (185 in the TAC arm, 188 in the DD AC→P arm, and 167 in the DD AC→PG arm). Death had occurred in 397 patients following breast cancer recurrence or contralateral breast cancer (133 in the TAC arm, 139 in the DD AC→P arm, and 125 in the DD AC→PG arm). OS analysis demonstrated similar survival rates across all treatment arms (Fig 2B). The 5-year OS for DD AC→PG (the investigational arm) compared with DD AC→P was 90.8% versus 89.1% (HR, 0.85; 95% CI, 0.69 to 1.05; $P = .13$), and OS for DD AC→PG compared with that for TAC was 90.8% versus 89.6% (HR, 0.86; 95% CI, 0.70 to 1.07; $P = .17$). The HR for OS of DD AC→P versus TAC was 1.01 (95% CI, 0.82 to 1.23; $P = .96$). OS and comparisons among treatment arms by ER status and nodal status are shown in Appendix Figures A3 and A4 (online only). There were no differences in the three arms in any ER or nodal subset. Five-year recurrence-free interval and distant recurrence-free interval were 85% to 87%, with no differences among the three arms (Kaplan-Meier curves for recurrence-free interval and distant recurrence-free interval are shown in Appendix Fig A5, online only).

Results from multiple Cox proportional hazards models, adjusting age at study entry (≥ 50 years, < 50 years), number of positive lymph nodes (4+, 1-3), estrogen receptor status, and radiation therapy and type of surgery (lumpectomy, mastectomy without radiotherapy v mastectomy with local or regional radiotherapy) did not show

significant differences in DFS or OS among the three treatment arms (Appendix Tables A3 and A4, online only). Women with one to three positive lymph nodes, ER-positive tumors, and smaller tumors and those who had received radiotherapy had significantly less risk of DFS events or death as a result of any cause. Among patients who received radiotherapy, there was no difference in the risk of DFS events or death between patients with regional radiotherapy and those without regional radiotherapy, regardless of the surgery type.

Safety

Toxicity from protocol therapy was acceptable for the adjuvant setting and typical for the regimens used. Grade 3 or 4 toxicities of note for TAC, DD AC→P, and DD AC→PG, respectively, were febrile neutropenia (9%, 3%, 3%; $P < .001$), sensory neuropathy ($< 1\%$, 7%, 6%; $P < .001$), and diarrhea (7%, 2%, 2%; $P < .001$) shown in Table 2. More patients in the TAC arm were hospitalized than in the other two arms: 347 (7.2%) in TAC, 237 (4.9%) in DD AC→P, and 266 (5.5%) in DD AC→PG ($P < .001$). Growth factor support with pegfilgrastim or filgrastim was used in 98% of patients receiving TAC at each cycle and 98% of patients in the DD arms at each cycle up to cycle 6, then 94% and 97% at cycle 7, 87% and 93% at cycle 8 for the DD AC→P and DD AC→PG arms, respectively. There were 25 deaths on treatment: 13 in the TAC arm, five in the DD AC→P arm, and seven in the DD AC→PG arm ($P = .2$). The causes of death by arm are listed in Appendix Table A5 (online only). Acute myeloid leukemia or myelodysplastic syndrome were reported in 5, 8, and 11 patients ($P = .46$), respectively.

Use of ESAs

Among 4,841 patients with follow-up data, 2,149 (44.4%) received an ESA (epoetin alfa or darbepoetin alfa). Hemoglobin < 10 mg/dL was reported in 12% of patients in the TAC arm, 26% in the DD AC→P arm, and 33% in the DD AC→PG arm. ESA use occurred in 563 (35%), 760 (47%), and 826 (51%) patients, respectively ($P < .001$); 3.7%, 6.3%, and 9.3% received transfusions, respectively

Fig 3. Hazard ratios (HRs) for disease-free survival in the National Surgical Adjuvant Breast and Bowel Project B-38 trial, according to stratification groups for (A) doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine (AC→PG) compared with concurrent administration of all three agents (TAC); (B) AC→PG compared with doxorubicin and cyclophosphamide followed by paclitaxel (AC→P); and (C) AC→P compared with TAC. LN, lymph node.

($P < .001$). Patients who received ESAs had similar incidences of second primary cancer compared with those who did not receive ESA support (4.3% v 3.8%; $P = .35$). In an unplanned analysis using a multivariate Cox proportional hazards model, ESA use showed no association with risk of DFS events after adjusting for treatment, age, tumor size, number of positive nodes, and surgery type (HR, 1.02;

Table 2. Grade 3 or 4 Adverse Events, According to Treatment Group in the NSABP B-38 Trial

Adverse Event	TAC (n = 1,607)		AC→P (n = 1,623)		AC→PG (n = 1,612)		P
	No.	%	No.	%	No.	%	
Febrile neutropenia	144	9	48	3	51	3	< .001
Infection with neutropenia	22	1	8	< 1	3	< 1	< .001
Allergic reaction	9	< 1	26	2	18	< 1	.03
Anemia (hemoglobin < 8 g/dL)	3	< 1	27	2	25	2	< .001
Arthralgia/myalgia	66	4	186	11	196	12	< .001
Fatigue	148	9	132	8	164	10	.15
Nausea	63	4	50	3	52	3	.43
Vomiting	45	3	45	3	49	3	.93
Mucositis	15	< 1	8	< 1	18	1	.21
Diarrhea	110	7	33	2	38	2	< .001
Thrombosis or embolism	37	2*	25	2	43	3	.23
Sensory neuropathy	16	< 1	117	7	99	6	< .001
Left ventricular dysfunction	5	< 1	0	0	0	0	.04

Abbreviations: AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; NSABP B-38, National Surgical Adjuvant Breast and Bowel Project B-38 [trial]; TAC, docetaxel, doxorubicin and cyclophosphamide.

*Grade 5 toxicity in two patients.

95% CI, 0.90 to 1.17; $P = .95$; Fig 4). Compared with patients who did not receive ESAs, treatment efficacy appeared to be similar in those who ever received ESAs (interaction $P = .71$).

Fig 4. Kaplan-Meier analyses of disease-free survival with respect to erythropoiesis-stimulating agent usage in the National Surgical Adjuvant Breast and Bowel Project B-38 trial. There was no association with risk of disease-free survival with a hazard ratio (HR) of 1.02 (95% CI, 0.90 to 1.17; $P = .95$) after adjusting for treatments, age, tumor size, number of positive nodes, and surgery type. EPO, epoetin alfa or darbepoetin alfa (erythropoiesis-stimulating agent). W/O, without.

DISCUSSION

In this phase III trial, the addition of G to DD AC→P did not improve outcomes. In addition, no significant differences in efficacy end points were identified between the investigational arm DD AC→PG and TAC; however, toxicity profiles differed with greater incidences of febrile neutropenia and diarrhea with TAC and greater incidences of neuropathy, anemia, transfusions, and ESA use with DD AC→P and AC→PG.

Anthracyclines and taxanes are among the most active and commonly used chemotherapeutic agents for the treatment of early-stage breast cancer. Several dosing regimens are commonly used and include concurrent, standard-dose sequential, and dose-dense sequential regimens. On the basis of the findings of the Cancer and Leukemia Group B 9741 trial (A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women With Node Positive Stage II/IIIA Breast Cancer), which demonstrated significantly improved DFS and OS with dose-dense regimens over conventionally scheduled regimens (risk ratio, 0.74 [$P = .01$] and 0.69 [$P = .01$], respectively), DD AC→P is considered to be one of the most effective P-based adjuvant chemotherapy regimens.²

Similarly, six cycles of TAC, used in this trial, appear to represent an optimal docetaxel-based adjuvant chemotherapy regimen on the basis of findings from two clinical trials.^{9,10} The Breast Cancer International Research Group 005 trial (Docetaxel in Breast Cancer) showed equal efficacy between six cycles of TAC and four cycles each of sequential AC followed by docetaxel (AC→T; OS: 88% v 89%, respectively; HR, 0.91; $P = .37$), and the NSABP B-30 trial (Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA [cT1-3, N0-1, M0] Breast Cancer and Positive Axillary Lymph Nodes) demonstrated that AC→T was superior to four cycles of TAC with respect to DFS (74% v 69%; HR 0.83; $P = .01$).

Because efficacy among standard triplet anthracycline- and taxane-based regimens for early-stage breast cancer was not statistically different in this large, randomized study, patients and physicians can choose among the most effective adjuvant chemotherapy regimens on the basis of consideration of toxicity profiles and schedule.

In an unplanned analysis of ESA usage, no difference in DFS was observed among treatment arms. The demographics of the two comparison groups were similar, and the analysis was adjusted for stratification factors. Although these results must be considered exploratory since ESA usage was not randomly assigned, the prospectively collected information in this large trial with mature follow-up suggests that usage based on physician discretion did not have an appreciable impact on the outcome of the group of patients who received the supportive therapy. These results support those reported by Moebus et al^{16,17} showing the use of epoetin alfa with adjuvant DD epirubicin, P, and carboplatin had no influence on DFS and OS in patients with high-risk breast cancer. Nitz et al¹⁸ found no difference in event-free survival or OS in patients receiving adjuvant TAC or fluorouracil, epirubicin, and C who were then randomly assigned to receive darbepoetin alfa or not. However, those results contrast with results from the recent PREPARE (Preoperative Epirubicin Paclitaxel Aranesp Study) trial, which showed a trend toward worse DFS in patients randomly assigned to receive darbepoetin alfa as part of a neoadjuvant

chemotherapy regimen for primary breast cancer.¹⁹ Unfortunately, further investigation in this area will probably not occur.

We have learned much over the last decade about the optimal treatment of early-stage breast cancer. However, attempts to improve outcomes with combination regimens by adding additional chemotherapeutic agents to anthracyclines, taxanes, and cyclophosphamide have not been successful. Trials incorporating capecitabine into anthracycline- and taxane-based regimens in early-stage breast cancer have shown no differences in long-term outcomes.^{20,21} Furthermore, our study showed no benefit with the addition of G to a sequential anthracycline- and taxane-based regimen, confirming results of the tAnGo trial (tAnGo, A Phase III Randomised Trial Of Gemcitabine In Paclitaxel-Containing, Epirubicin-Based, Adjuvant Chemotherapy For ER/PgR-Poor, Early Stage, Breast Cancer), which showed that the addition of gemcitabine to sequential epirubicin and C followed by P conferred no therapeutic benefit for patients with early-stage breast cancer.²² It also seems unlikely that further changes in dosing schedules will result in appreciable gains. The future lies in studies that will help us determine appropriate treatments based on tumor biology. Examples include the ongoing MINDACT (Microarray in Node-Negative and 1-3 Node-Positive Disease May Avoid Chemotherapy) trial that will study gene expression profiling versus clinical assessment in determining the need for chemotherapy in women with node-negative breast cancer.²³ The TAILORx (Trial Assigning Individualized Options for Treatment) study will help shed light on the benefits of adding chemotherapy to hormonal therapy for women with node-negative, ER-positive breast cancer with midrange Oncotype DX (Genomic Health, Redwood City, CA) recurrence scores, and the RxPONDER (Rx for Positive Node, Endocrine Responsive Breast Cancer) study will determine the effect of endocrine therapy with or without chemotherapy in patients with node-positive breast cancer who do not have high Oncotype DX recurrence scores.^{24,25} We have made much progress identifying chemotherapy strategies for the treatment of breast cancer. We must now turn to biology, in which larger gains for success in breast cancer therapy are more likely.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Authors marked with an asterisk () are participants in ASCO's Disclosure Management System Pilot; their disclosure is not limited to subject matter under consideration in this article and includes payments to themselves, an immediate family member (I), and/or their institutions (INST). For information on the pilot program, or to provide feedback, please visit coipilot.asco.org.*

Employment or Leadership Position: None **Consultant or Advisory Role:** Eleftherios P. Mamounas, sanofi-aventis (C), Eli Lilly (C); *Sandra M. Swain, Genentech/Roche (U) **Stock Ownership:** None **Honoraria:** André Robidoux, Amgen Canada, Eleftherios P. Mamounas, sanofi-aventis **Research Funding:** *Sandra M. Swain,

Genentech/Roche, sanofi-aventis, Puma, Safeway, Bristol-Meyers Squibb, BiPar Sciences **Expert Testimony:** None **Patents:** None **Other Remuneration:** None

AUTHOR CONTRIBUTIONS

Conception and design: Sandra M. Swain, Gong Tang, Charles E. Geyer Jr, André Robidoux, Edward A. Levine, John L. Zapas, Soonmyung Paik, Joseph P. Costantino, Eleftherios P. Mamounas, Norman Wolmark
Administrative support: Sandra M. Swain, Joseph P. Costantino, Norman Wolmark

Provision of study materials or patients: Louis Fehrenbacher, Catherine A. Azar, André Robidoux, Adam M. Brufsky, David D. Biggs, Edward A. Levine, Donald W. Northfelt

Collection and assembly of data: Sandra M. Swain, Gong Tang, Charles E. Geyer Jr, Priya Rastogi, James N. Atkins, Paul P. Donnellan, Louis Fehrenbacher, Catherine A. Azar, Jonathan A. Polikoff, Adam M. Brufsky, David D. Biggs, Edward A. Levine, John L. Zapas, Louise Provencher, Soonmyung Paik, Joseph P. Costantino

Data analysis and interpretation: Sandra M. Swain, Gong Tang, Charles E. Geyer Jr, Priya Rastogi, Louis Fehrenbacher, André Robidoux, Jonathan A. Polikoff, Donald W. Northfelt, Soonmyung Paik

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

- Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. *J Clin Oncol* 21:976-983, 2003
- Citron ML, Berry DA, Cirincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J Clin Oncol* 21:1431-1439, 2003
- Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. *N Engl J Med* 352:2302-2313, 2005
- Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. *J Clin Oncol* 23:3686-3696, 2005
- Roché H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. *J Clin Oncol* 24:5664-5671, 2006
- Coudert B, Camponne M, Spielmann M, et al: Benefit of the sequential administration of docetaxel after standard FEC regimen for node-positive breast cancer: Long-term follow-up results of the FNCLCC-PACS 01 trial. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 603)
- Di Leo A, Francis P, Crown J, et al: Overall survival benefit for sequential doxorubicin-docetaxel compared to concomitant doxorubicin and docetaxel in node-positive breast cancer: 8-Yr. results of the Breast International Group (BIG) 2-98 phase III adjuvant trial. Presented at 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 601)
- Laporte S, Jones S, Chapelle C, et al: Consistency of effect of docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: Meta-analysis of 12 randomized clinical trials. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (abstr 605)
- Swain SM, Jeong JH, Geyer CE Jr, et al: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. *N Engl J Med* 362:2053-2065, 2010
- Eiermann W, Pienkowski T, Crown J, et al: Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIrg-005 Trial. *J Clin Oncol* 29:3877-3884, 2011
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet* 379:432-444, 2012
- Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. *J Clin Oncol* 26:3950-3957, 2008
- Colomer R, Llombart-Cussac A, Lluch A, et al: Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. *Ann Oncol* 15:201-206, 2004
- Colomer R: Gemcitabine and paclitaxel in metastatic breast cancer: A review. *Oncology (Williston Park)* 18:8-12, 2004
- American Joint Committee on Cancer (AJCC). *AJCC Cancer Staging Manual* (ed 6). New York, NY, Springer-verlag, 2002
- Moebus V, Lueck H, Thomssen C, et al: The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). *J Clin Oncol* 25: 20s, 2007 (suppl; abstr 569)
- Moebus V, Jackisch C, Lueck HJ, et al: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. *J Clin Oncol* 28:2874-2880, 2010
- Nitz U, Gluz O, Oberhoff C, et al: Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: Survival and quality of life analysis from the prospective randomized WSG ARA Plus trial. Presented as a poster discussion at the 34th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011 (abstr PD07-06)
- Untch M, von Minckwitz G, Konecny GE, et al: PREPARE trial: A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—Outcome on prognosis. *Ann Oncol* 22:1999-2006, 2011
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al: FinXX final 5-year analysis: Results of the randomised, open label, phase III trial in medium-to-high risk early breast cancer. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S4-1)
- O'Shaughnessy J, Paul D, Stokoe C, et al: First efficacy results of a randomized, open-label, phase II study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S4-2)
- Poole CJ, Hiler L, Howard HC, et al: tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). *J Clin Oncol* 26:8s, 2008 (suppl; abstr 506)
- ClinicalTrials.gov: Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women with Breast Cancer That Involves No More Than 3 Lymph Nodes. <http://clinicaltrials.gov/ct2/show/NCT00433589?term=mindact&rank=1>
- ClinicalTrials.gov: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial). <http://clinicaltrials.gov/ct2/show/NCT00310180?term=NCT00310180&rank=1>
- ClinicalTrials.gov: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer. <http://clinicaltrials.gov/ct2/show/NCT01272037?term=NCT01272037&rank=1>

Affiliations

Sandra M. Swain, Gong Tang, Charles E. Geyer Jr, Priya Rastogi, James N. Atkins, Paul P. Donnellan, Louis Fehrenbacher, Catherine A. Azar, André Robidoux, Jonathan A. Polikoff, Adam M. Brufsky, David D. Biggs, Edward A. Levine, John L. Zapas, Louise Provencher, Soonmyung Paik, Joseph P. Costantino, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project (NSABP);

Norman Wolmark, Allegheny General Hospital, Allegheny Health Network; Gong Tang and Joseph P. Costantino, NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health; Priya Rastogi, University of Pittsburgh Cancer Institute; Adam M. Brufsky, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra M. Swain, MedStar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University, Richmond, VA; James N. Atkins, Southeast Cancer Control Consortium-Community Clinical Oncology Program, Goldsboro; Edward A. Levine, Wake Forest University, Winston-Salem, NC; Paul P. Donnellan, University Hospital, Galway, and the All-Ireland Cooperative Oncology Research Group, Dublin, Ireland; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Jonathan A. Polikoff, Kaiser Permanente Southern California, San Diego, CA; Catherine A. Azar, Kaiser Permanente, Denver, CO; André Robidoux, Centre hospitalier de l'Université de Montréal (CHUM), Montréal; Louise Provencher, CHU de Québec, Hôpital du Saint-Sacrement, Québec City, QC, Canada; David D. Biggs, Helen F. Graham Cancer Center, Christiana Care Health System, Newark, DE; John L. Zapas, Medstar Franklin Square Medical Center, Baltimore, MD; Donald W. Northfelt, Mayo Clinic Arizona, Scottsdale, AZ; and Eleftherios P. Mamounas, MD Anderson Cancer Center, Orlando, FL.

***Journal of Oncology Practice* Available on PubMed Central**

Full text for all *Journal of Oncology Practice* (JOP) articles is available on the NIH PubMed Central archive 4 months after publication. Content is then delivered to PubMed, a metadata repository overseen by the National Library of Medicine and used by many scientific, technical, and medical researchers, making JOP material discoverable in PubMed.

Find yourself in PubMed. Submit your manuscript to JOP at jop.msubmit.net.

Appendix

Table A1. Treatment Discontinuation (N = 4,883)

Variable	TAC		AC→P		AC→PG		Total	
	No.	%	No.	%	No.	%	No.	%
Treatment completed per protocol	1,485	91	1,431	88	1,437	88	4,353	89
Adverse events/complications	66	4	141	9	105	6	312	6
Patient withdrawal or refusal	39	2	32	2	48	3	119	2
Alternative therapy	10	< 1	7	< 1	13	< 1	30	< 1
Death, recurrence or second primary cancer	11	< 1	8	< 1	5	< 1	24	< 1
Other	13	< 1	12	< 1	20	1	45	< 1
Total	1,624		1,631		1,628		4,883	

Abbreviations: AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; TAC, docetaxel, doxorubicin and cyclophosphamide.

Table A2. First DFS Events in the Intention-to-Treat Population in the NSABP B-38 Trial

Event Type	TAC (n = 1,610)		AC→P (n = 1,618)		AC→PG (n = 1,613)		Total (N = 4,841)	
	No.	%	No.	%	No.	%	No.	%
Recurrence								
Locoregional	47	3	44	3	59	4	150	3
Distant	188	12	176	11	181	11	545	11
Contralateral breast cancer	21	1	21	1	27	2	69	1
Other second primary	42	3	33	2	38	2	113	2
Death due to other causes	29	2	20	1	15	1	64	1
Overall number of DFS events	327	20	294	18	320	20	941	19

Abbreviations: AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; DFS, disease-free survival; NSABP B-38, National Surgical Adjuvant Breast and Bowel Project B-38 [trial]; TAC, docetaxel, doxorubicin and cyclophosphamide.

Table A3. Multiple Cox Proportional Hazard Model for DFS in the NSABP B-38 Trial

Variable	HR	95% CI	P
AC→P v TAC	0.89	0.75 to 1.04	.15
AC→PG v TAC	0.96	0.82 to 1.13	.62
Age ≥ 50 v < 50 years	0.91	0.80 to 1.04	.18
4+ nodes v 1-3 nodes	2.03	1.75 to 2.36	< .001
ER-positive v ER-negative	0.44	0.39 to 0.51	< .001
Tumor size (cm)*	1.18	1.11 to 1.24	< .001
Mastectomy + no radiotherapy v mastectomy + radiotherapy	1.36	1.09 to 1.69	.007
Lumpectomy v mastectomy + radiotherapy	1.05	0.89 to 1.24	.57

Abbreviations: AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; DFS, disease-free survival; ER, estrogen receptor; HR, hazard ratio; NSABP B-38, National Surgical Adjuvant Breast and Bowel Project B-38 [trial]; TAC, docetaxel, doxorubicin and cyclophosphamide.

*All tumors with size larger than 5 cm were assigned as 5 cm.

Table A4. Multiple Cox Proportional Hazard Model for OS in the NSABP B-38 Trial

Variable	HR	95% CI	P
AC→P v TAC	1.04	0.84 to 1.29	.70
AC→PG v TAC	0.91	0.73 to 1.13	.38
Age ≥ 50 v < 50 years	1.01	0.84 to 1.21	.92
4+ nodes v 1-3 nodes	2.89	2.36 to 3.55	< .001
ER-positive v ER-negative	0.35	0.29 to 0.42	< .001
Tumor size (cm)*	1.17	1.09 to 1.27	< .001
Mastectomy + no radiotherapy v mastectomy + radiotherapy	1.33	0.99 to 1.79	.06
Lumpectomy v mastectomy + radiotherapy	0.97	0.77 to 1.20	.75

Abbreviations: AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; ER, estrogen receptor; HR, hazard ratio; NSABP B-38, National Surgical Adjuvant Breast and Bowel Project B-38 [trial]; OS, overall survival; TAC, docetaxel, doxorubicin and cyclophosphamide.

*All tumors with size larger than 5 cm were assigned as 5 cm.

Table A5. Reported Causes of Deaths on Treatment

Toxicity	No. of Patients			Total
	TAC	AC→P	AC→PG	
Cardiac ischemia/infraction	1	0	0	1
Pericarditis	0	1	0	1
Death not associated with CTCAE term "death NOS"	0	1	0	1
Diabetes	0	0	1	1
Colitis	0	0	1	1
GI small bowel necrosis, NOS	1	0	0	1
CNS hemorrhage	0	0	1	1
Liver dysfunction	1	0	2	3
Blood infection (documented clinically)	3	0	0	3
Lung infection (pneumonia; documented clinically)	1	0	0	1
Peritoneal cavity infection (documented clinically)	0	1	0	1
Infection, other (specify)	1	0	0	1
Infection with normal blood ANC	1	1	1	3
Hypoglycemia	1	0	0	1
Pneumonitis	0	1	0	1
Pulmonary, other (specify)	1	0	1	2
Thrombosis/thrombus/embolism	2	0	0	2
Total	13	5	7	25

Abbreviations: AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; ANC, absolute neutrophil count; CTCAE, Common Terminology Criteria for Adverse Events; NOS, not otherwise specified; TAC, docetaxel, doxorubicin and cyclophosphamide.

Fig A1. Kaplan-Meier estimates of disease-free survival among patients with (A) estrogen receptor (ER) –negative tumors or (B) ER-positive tumors across all three treatment arms in the National Surgical Adjuvant Breast and Bowel Project B-38 trial. AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; HR, hazard ratio; TAC, docetaxel, doxorubicin, and cyclophosphamide.

Fig A2. Kaplan-Meier estimates of disease-free survival among patients with (A) 1 to 3 or (B) 4+ positive lymph nodes across all three treatment arms in the National Surgical Adjuvant Breast and Bowel Project B-38 trial. AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; HR, hazard ratio; TAC, docetaxel, doxorubicin, and cyclophosphamide.

Fig A3. Kaplan-Meier estimates of overall survival in patients with (A) estrogen receptor (ER) –negative or (B) ER-positive tumors across all treatment arms in the National Surgical Adjuvant Breast and Bowel Project B-38 trial. AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; HR, hazard ratio; TAC, docetaxel, doxorubicin, and cyclophosphamide.

Fig A4. Kaplan-Meier estimates of overall survival in patients with (A) 1 to 3 or (B) 4+ positive lymph nodes across all treatment arms in the National Surgical Adjuvant Breast and Bowel Project B-38 trial. AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; HR, hazard ratio; TAC, docetaxel, doxorubicin, and cyclophosphamide.

Fig A5. Kaplan-Meier estimates of (A) recurrence-free interval and (B) distant recurrence-free interval across all treatment arms in the National Surgical Adjuvant Breast and Bowel Project B-38 trial. AC→P, doxorubicin and cyclophosphamide followed by paclitaxel; AC→PG, doxorubicin and cyclophosphamide followed by paclitaxel and gemcitabine; HR, hazard ratio; TAC, docetaxel, doxorubicin, and cyclophosphamide.